02
Everyone else sells half the answer.
Energy vendors have no placement robot. Robot vendors have no energy of their own. Epione is open architecture, so it can walk into an account running competitor energy and become the wedge that converts it.
The field.
| Company | Energy | Placement robot | Our angle |
|---|---|---|---|
| Precision IO NeuWave and Epione | Microwave | Yes, FDA cleared | The combined offer. Lead with it. |
| Medtronic Emprint | Microwave | None announced | The largest microwave rival. Place Epione beside Emprint, then compete for the energy. |
| AngioDynamicsSource Solero, NanoKnife | Microwave, IRE | None announced | NanoKnife is cleared for prostate tissue. IRE needs several needles placed precisely, which is what Epione plans. |
| Boston Scientific Cryoablation | Cryo | None announced | Cryo uses many probes. Robotic planning helps most here. |
| XACT RoboticsSource XACT ACE | None of its own | Yes, CT guided | The most direct robot rival. Win with the bundle and the installed base. |
| Interventional Systems Micromate | None of its own | Yes | Compact and lower cost. Compete on the full workflow and AI planning. |
Robot status for energy vendors reflects public announcements as of October 2026. I would validate it in the field.
Strong hand, early integration, real rivals.
Strengths
- NeuWave installed base: microwave ablation used in 70%+ of top US cancer centersSource
- Epione robot: 1,400+ patients treated; open architecture works with any energy
- AI planning and GE angiography integration
Weaknesses
- US label covers abdominal ablation with CT only
- Two sales teams still run separately
- US clinical evidence is still building
- Reimbursement: robotic guidance is not paid separately
- CT suite time: robot setup competes with a full CT schedule
Opportunities
- Pull through: place Epione robots in the hospitals already using NeuWave
- Conquest of accounts on nonrobotic energy
- New indications: kidney, bone, lung, then prostate
Threats
- Customer doubt after J&J's exit signal
- Robot rivals are already cleared
- Tight capital budgets at health systems
- Lower cost guidance: compact robots like Micromate compete on price